Full Press Release Details
CEO, Steven Lydeamore presentation to Emerging Growth Conference
Australia, October 23, 2025: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore
will be presenting virtually at the Emerging Growth Conference on Wednesday 22nd October 2025 (4:10pm - 4:20pm U.S. Eastern
copy of the presentation being made Is included below.
release has been authorised by the directors of Immuron Limited.
Chief Executive Officer
Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered
targeted polyclonal antibodies for the treatment of infectious diseases.
is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers' diarrhea,
a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan is a highly purified
tabletized preparation of hyper immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing bacteria
and prevent colonization and the pathology associated with travelers' diarrhea. In Australia, Travelan is a listed medicine
on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travelers' Diarrhea, reduce
the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan is a licensed natural health product (NPN
80046016) and is indicated to reduce the risk of Travelers' Diarrhea. In the U.S., Travelan is sold as a dietary supplement
for digestive tract protection.
is generally defined as the passage of 3 unformed stools per 24 hours plus at least one additional symptom (such as nausea, vomiting,
abdominal cramps, fever, blood/mucus in the stools, or fecal urgency) that develop while abroad or within 10 days of returning from any
resource-limited destinations (Leung et al., 2006). Diarrhea continues to be the most frequent health problem among travelers to destinations
in lower- and middle-income regions (Steffen, 2017). Deployed US military personnel, essentially representing a long-term traveller population,
are particularly affected given their population dynamics and the context in which they seek care and treatment (Connor et al., 2012).
Diarrhea is the leading infectious disease threat to the overall health and preparedness of deployed US armed forces, with diarrheagenic
E. coli, Campylobacter spp., and Shigella spp. among the most commonly reported etiologies (Riddle et al., 2006).
proprietary technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum. Immuron has
the capability of producing highly specific immunoglobulins to any enteric pathogen and our products are orally active. Bovine IgG can
withstand the acidic environment of the stomach and is resistant to proteolysis by the digestive enzymes found in the Gastrointestinal
(GI) tract. Bovine IgG also possesses this unique ability to remain active in the human GI tract delivering its full benefits directly
to the bacteria found there. The underlying nature of Immuron's platform technology enables the development of medicines across
a large range of infectious diseases. The platform can be used to block viruses or bacteria at mucosal surfaces such as the Gastrointestinal
tract and neutralize the toxins they produce.
was developed using Immuron's platform technology. IMM-124E is produced from the colostrum of birthing cattle that have been immunised
during pregnancy with a vaccine containing the outer antigens of multiple human derived ETEC. A total of 13 ETEC strains are used in
the vaccine to produce high levels of antibodies against selected surface antigens from the most common strains of ETEC. (Otto et al.,
resultant hyperimmune colostrum IMM-124E from ETEC vaccinated cows contains significant levels of polyclonal antibodies specific for
ETEC antigens LPS, CFA-I and Flagellin (Sears et al., 2017).
antibodies produced in IMM-124E have been found to have a stronger binding and neutralizing activity (than the antibodies of unvaccinated
cattle) against a wide range of LPS antigens including both the variable O-polysaccharide region and the preserved oligosaccharide core
R' region of LPS from the 13 serotypes used in the ETEC vaccine.
is manufactured into a tablet form referred to as Travelan .
is developing IMM-529 as an adjunctive therapy in combination with standard of care antibiotics for the prevention and/or treatment of
recurrent Clostridioides difficile infection (CDI). IMM-529 antibodies targeting Clostridioides difficile (C. diff) may help to clear
CDI infection and promote a quicker re-establishment of normal gut flora, providing an attractive oral preventative for recurrent CDI.
is collaborating with Dr. Dena Lyras and her team at Monash University, Australia to develop vaccines to produce bovine colostrum-derived
antibodies. Dairy cows were immunised to generate hyperimmune bovine colostrum (HBC) that contains antibodies targeting three essential
C. diff virulence components. IMM-529 targets Toxin B (TcB), the spores and the surface layer proteins of the vegetative cells.
unique 3-target approach has yielded promising results in pre-clinical infection and relapse models, including (1) Prevention of primary
disease (80% P =0.0052); (2) Protection of disease recurrence (67%, P <0.01) and (3) Treatment of primary disease (78.6%, P<0.0001;
TcB HBC). Importantly IMM-529 antibodies cross-react with whole cell lysates of many different human strains of C. diff including hypervirulent
our knowledge, IMM-529 is, to date, the only investigational drug that has shown therapeutic potential in all three phases of the disease
(Hutton et al., 2017).
has an exclusive distribution agreement with Calmino goup AB for the territories of Australia and New Zealand for ProIBS . ProIBS
- to help patients treat IBS symptoms ProIBS is a certified medical device for the treatment of IBS symptoms such as abdominal pain,
bloating and unsettled bowel movements (diarrhoea and/or constipation). ProIBS contains AVH200 , derived from the plant Aloe
barbadensis. Mill. AVH200 has gel forming components which support the intestinal mucosal barrier. As IBS is known to affect individuals
for a long period of time, it is essential to have a treatment appropriate for long- term use -as ProIBS is. The product is
safe, and no interactions with other medications are known. Science-driven innovative Calmino group AB, the developer of ProIBS ,
conducted a usability study among 1,003 users. PROIBS was helpful for 94% of them. 91% of the users experienced an improvement in
daily life and 98% would recommend PROIBS to someone else. To learn more please check: www.proibs.eu.
bowel syndrome (IBS) is a common condition where you experience symptoms related to your digestive system. This is sometimes linked
to certain foods, lifestyle habits and stress levels or mood. IBS affects around 3 out of every 10 people. Females are more likely
than males to be affected. Some key symptoms of IBS include: abdominal pain or discomfort; stomach bloating and wind; chronic
diarrhoea or constipation, or alternating between the two.(healthdirect.gov.au) According to available data, the IBS treatment
market in Australia is estimated to be a part of the broader "Digestives & Intestinal Remedies" market, generating a
revenue of around AU$221.14 million in 2025, with a projected annual growth rate of 3.28%.(Statista)
P, Porter CK, Swierczewski B and Riddle MS. Diarrhea during military deployment: current concepts and future directions. Curr Opin Infect
Dis. 25(5): 546-54; 2012.
M.L., Cunningham, B.A., Mackin, K.E. et al. Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent
antibiotic alternative. Sci Rep 7, 3665 (2017). https://doi.org/10.1038/s41598-017-03982-5
AK, Robson WL, Davies HD. Travelers' diarrhea. Adv Ther. Jul-Aug; 23(4): 519-27; 2006
W, Najnigier B, Stelmasiak T and Robins-Browne RM. Randomized control trials using a tablet formulation of hyperimmune bovine colostrum
to prevent diarrhea caused by enterotoxigenic Escherichia coli in volunteers Scandinavian Journal of Gastroenterology 46: 862-
MS, Sanders JW, Putnam SD, and Tribble DR. Incidence, etiology, and impact of diarrhea among long-term travelers' (US military
and similar populations): A systematic review. American Journal of Tropical Medicine and Hygiene. 74(5): 891-900; 2006.
KT, Tennant SM, Reymann MK, Simon R, Konstantopolos N, Blackwelder WC, Barry EM and Pasetti MF. Bioactive Immune Components of Anti-Diarrheagenic
Enterotoxigenic Escherichia coli Hyperimmune Bovine Colostrum products. Clinical and Vaccine Immunology. 24 (8) 1-14; 2017.
R. Epidemiology of travelers' diarrhea. J Travel Med. 24(suppl_1): S2-S5; 2017.
more information visit: https://www.immuron.com.au/ and https://www.travelan.com
Subscribe to Immuron's InvestorHub: Here
press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements
relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking
statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect
our business, operating results, financial condition, and stock value. Factors that could cause actual results to differ materially from
those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing
and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the
timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party
suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial
additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our
SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in our expectations or any changes in events, conditions, or circumstances on which
any such statement is based, except as required by law.
EMERGING GROWTH CONFERENCE 22 OCTOBER 2025 S teve n Lyde a m ore - C EO NASDAQ: IMRN ASX: IMC
Certain statements made in this presentation are forward - looking statements and are based on Immuron's current expectations, estimates and projections. Words such as " anticipates," "expects," "intends," "plans," "believes," " seeks," "estimates," "guidance" and s imilar expressions are intended to identify forward - looking statements. Although Immuron believes the forward - looking statements are based on reasonable assumptions, they are subject to certain r i sks and uncertainties, some of which are beyond Immuron's control, including those r i sks or uncertainties inherent in the process of both developing and commercializing technology. As a result, actual results could materially differ f rom those expressed or forecasted in the forward - looking statements. The forward - looking statements made in this presentation relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward - looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by l aw or by any appropriate regulatory authority. FY 2026 results in this presentation are subject to audit review. SAFE HARBOR STATEMENT
3 Q1, FY26 Global Sales Revenue of A$2.0 million up 34% on Q1, FY25 ProIBS to be launched in Australia in October 2025 Clinical Development Travelan IMM - 124E: 1H 2026: End of Phase 2 FDA meeting (Phase 2; n=60) IMM - 529 (CDI): Immuron anticipates FDA approval of IND in December 2025 Results, Upcoming Milestones & Outlook Executive summary Three commercial products: Three clinical programs : Travelan (traveller's diarrhoea), Protectyn and ProIBS (irritable bowel syndrome) Travelan : IMC: Phase 2 CHIM trial (n=60) Travelan : USU: Field Study (n=851) IMM - 529 (CDI): IMC: preparing IND for Phase 2 trial (n=60) Major Shareholders Financial Snapshot 269,353,813 Shares on Issue 13,540,315 Total Options IMC: A$0.084 Last Traded Price IMC: A$0.10/0.054 IMRN: $2.483/1.50 52 week High/Low IMC: A$22.6m Market Cap A$5.9m Cash & Term Deposit (30 June 2025) - Excludes A$2.8m raised from US placement (July 2025) % of CSO Units Holder 42.09 % 113,372,424 BNY Mellon Asset Management 2.04 % 5,500,000 Authentics Australia Pty. Ltd. 1.49% 4,000,000 Dr Russell Kay Hancock 1.43 % 3,846,712 Grandlodge Pty Ltd 1.20 % 3,234,153 Management & Board Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases Company Overview Clinical: Travelan (IMM - 124E) Travelan Uniformed Services University IMM - 124E trial 100% of 851 participants have been randomized and deployed Travelan (IMM - 124E) Travelan Uniformed Services University IMM - 124E trial topline results anticipated by end of October 2025 IMM - 529 (CDI): Immuron completed submission of Investigational New Drug (IND) in October 2025 IMM - 986 (VRE): Colostrum manufactured for preclinical studies; initial pre - clinical studies are anticipated to be performed before the end of calendar2025 Business Update Commercial: Continued growth of Travelan sales ProIBS launch stock released for sale; launch in October 2025 FY25 Results: FY25 Global Sales Revenue of A$7.3 million up 49% on prior year - North American Travelan sales A$2.0 million up 76% on prior year Profit 1 from Hyperimmune products for FY25 was A$1.35m, the same as FY24; FY25 increased selling & marketing investment A$1.4m 1 Segment reporting; excludes Research & Development and Corporate segments.
1. FINANCIAL & OPERATIONAL HIGHLIGHTS
5 FY25 Financial Summary Global Sales Revenue $7.3m Up 49% Australian Sales Revenue $5.3m Up 40% North American Sales Revenue $2.0m Up 76% Gross Profit Margin 65.4% EBITDA (ex - R&D) 1 $(3.1)m $2.1m improvement Cash + Term Deposit $5.9m (excludes A$2.8m raised from the US placement) 2 1 ex - R&D : add back research & development, less R&D Tax Incentive and R&D grants ; 2 30 June 2025 , as reported in Immuron's Appendix 4 E (Cash $ 2 . 83 m ; Term Deposit $ 3 . 04 m) and excludes the A $ 2 . 8 m raised from the US placement of 32 . 9 m shares at the AUD equivalent of $ 0 . 0824 per share conducted on the Nasdaq : IMRN completed 17 July 2025 . The shares were purchased by US investors from Immuron's US At - The - Market ( ATM ) facility . The ATM facility has now been fully utilised .
6 Immuron Ltd is an Australian integrated biopharmaceutical company with global scale, focused on developing, and commercialising, oral immunotherapeutic for the treatment of gut mediated diseases Immuron Limited Vancouver, BC Canada Immuron Inc New York USA Immuron Global HQ Melbourne Australia Our Footprint: Australia, Canada & US Research & Development Ongoing clinical trials 3 pipeline assets in 2 clinical programmes Global footprint Australia, US, Canada and expanding Market Penetration New markets & expanding distribution channels Technology Platform Developing oral immunoglobulin technology Our Products Reduce the risk of Traveller's Diarrhoea Sold in pharmacies Australia - wide Available in Australia, USA and Canada Treatment of symptoms associated with Irritable Bowel Syndrome (IBS) To be sold in pharmacies Australia - wide Available in Australia
7 Travelan continued strong sales growth Global + FY2025 AUD$7.3 million up 49% on prior year + FY2026 Q1 AUD$2.0 million up 34% on FY2025 Q1 Australia + FY2025 AUD$5.2 million up 40% on prior year + FY2026 AUD$1.6 million up 52% on FY2025 Q1 North America + FY2025 AUD$2.0 million up 76% on prior year + FY2026 AUD$0.4 million down 8% on FY2025 Q1 + USA FY2026 AUD$0.4 million up 44% on FY2026 Q1 $ - $1,000,000 $2,000,000 $5,000,000 $4,000,000 $3,000,000 $6,000,000 $7,000,000 $8,000,000 Oct - Dec Jan - Mar Apr - Jun Global Year to Date Net Sales ($AUD) FY24 Jul - Se p FY25 $ - $1,000,000 $2,000,000 $3,000,000 $4,000,000 $5,000,000 $6,000,000 $7,000,000 $8,000,000 FY22 FY23 FY24 FY25 North America Australia
EXPANSION OF TRAVELAN DISTRIBUTION 8
2. CLINICAL DEVELOPMENT PROGRAM